Back to Search Start Over

OA20.02 Pre-Treatment Levels of ctDNA for Long-Term Survival Prediction in Stage IIIA NSCLC Treated With Neoadjuvant Chemo-Immunotherapy

Authors :
R. Laza Briviesca
Maria Rosario Garcia Campelo
Delvys Rodriguez Abreu
Margarita Majem
Roberto Serna
A. Insa
Manuel Domine
Guillermo López Vivanco
Ana Royuela
V. Calvo
B. Massuti
C. Benito
Isidoro Barneto
E. Pereira
R. Bernabé
Amândio Cruz
Estela Sánchez-Herrero
E. Del Barco
M. Casarrubios
Alex Martinez-Marti
E. Nadal
M. Cobo
M. Provencio
Nuria Viñolas
Amalia Pérez Romero
J. de Castro
Santiago Viteri
Source :
Journal of Thoracic Oncology. 16:S883-S884
Publication Year :
2021
Publisher :
Elsevier BV, 2021.

Abstract

Introduction: There are currently no predictive biomarkers for long-term survival after neoadjuvant chemoimmunotherapy. However, the identification of non-small lung cancer (NSCLC) patients who obtain long-term benefit from chemoimmunotherapy is essential to optimize therapies. Methods: Using samples from NADIM clinical trial (NCT03081689), in which resectable stage IIIA NSCLC patients were treated with neoadjuvant chemo-immunotherapy with nivolumab, we have evaluated the capacity of ctDNA levels before treatment initiation to predict overall survival (OS) and progression-free survival (PFS) by calculating Harrell’s C-statistic and we compare its predictive value with classical survival surrogates as the pathological response and clinical response assessed according to RECIST criteria v.1.1. The ctDNA was analyzed by NGS, using the Oncomine Pan-Cancer Cell-Free Assay™ (Thermo Fisher Scientific®). To explore the prognostic value of the amount of ctDNA at baseline, for each positive plasma sample, we calculated the sum of the mutant allele frequency (MAF) for all detected mutations. Patients who died from COVID19 were excluded from this analysis. Results: In our study, clinical responses based on RECIST criteria were not predictive for OS or PFS. On the contrary, in the multivariate analysis, patients with low ctDNA levels (

Details

ISSN :
15560864
Volume :
16
Database :
OpenAIRE
Journal :
Journal of Thoracic Oncology
Accession number :
edsair.doi...........b914e6d2abd85c9aad2f6cda8b8cbbab